<Disease><Name>TYROSINEMIA I</Name><Synonym>FUMARYLACETOACETATE HYDROLASE DEFICIENCY; HEPATORENAL TYROSINEMIA; TYROSINOSIS, ACUTA AND CHRONIC; FUMARYLACETOACETASE;</Synonym><OMIM><Number>276700</Number><URL>http://omim.org/entry/276700</URL></OMIM><Orphanet><Number>882</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=882</URL></Orphanet><Protein><Number>fumarylacetoacetase</Number><URL>http://www.uniprot.org/uniprot/P16930</URL></Protein><ExPASy><Number>3.7.1.2</Number><URL>http://enzyme.expasy.org/EC/3.7.1.2</URL></ExPASy><Gene>15q25.1Detail information to gene locus by the National Center for Biotechnology Information NCBI:

Fumarylacetoacetase
</Gene><ICD>E70.2</ICD><Summary>rare (1:1000000) ;autosomal recessive ;mutation in the FAH gene;2 types: ;- acute form (1-6 mo) ;- chronic form ;Hepatorenal tyrosinaemia (HT1) is a serious condition that used to be&#160; fatal before the advent of nitisinone (NTBC, Orfadine&#194;&#174;) as a therapeutic option [Das AM 2017]; In the Nitisinone era only those with unresponsive liver failure or suspected malignancy were considered for transplantation [McKirnan P 2017].</Summary><Symptoms><symtomp><id>2074</id><symptom>Amino acids, plasma</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2347</id><symptom>anemia</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM | LABORATORY FINDINGS</category></symtomp><symtomp><id>1738</id><symptom>ascites</symptom><category>BODY | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2323</id><symptom>behavior, abnormal or bizarre, confusion / behaviour, abnormal or bizarre</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2130</id><symptom>bleeding tendencies, hemorrhages / bleeding tendencies, hemorrhage</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2104</id><symptom>cardiomyopathy</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3677</id><symptom>cardiomyopathy, hypertrophic</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1997</id><symptom>cirrhosis or fibrosis of liver</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2133</id><symptom>Coagulopathy/Coagulation factors / Gerinnungsfaktoren [+]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1982</id><symptom>diarrhea</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2216</id><symptom>edema</symptom><category>SKIN</category></symtomp><symtomp><id>2095</id><symptom>failure to thrive</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp><symtomp><id>2374</id><symptom>Fanconi syndrome</symptom><category>GENERAL TOPICS | GENITOURINARY TRACT</category></symtomp><symtomp><id>1713</id><symptom>fever, severe or recurrent</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1988</id><symptom>gastrointestinal hemorrhage (bleeding)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1882</id><symptom>growth retardation, poor growth</symptom><category>GENERAL TOPICS | GENERAL TOPICS</category></symtomp><symtomp><id>3432</id><symptom>Hemolytic-uremic-syndrome</symptom><category>GENITOURINARY TRACT | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>3195</id><symptom>hypoglycemia</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1951</id><symptom>irritability</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1873</id><symptom>jaundice</symptom><category>LABORATORY FINDINGS | SKIN</category></symtomp><symtomp><id>1953</id><symptom>lethargy, drowsiness, apathy</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2487</id><symptom>liver carcinoma</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2380</id><symptom>liver failure</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1998</id><symptom>liver involvement or dysfunction</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>3175</id><symptom>melena</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp><symtomp><id>1922</id><symptom>nephrocalcinosis</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>2106</id><symptom>nephromegaly / renal enlargement (large kidneys)</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>3369</id><symptom>neuropathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2089</id><symptom>Organic acids, urine</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2158</id><symptom>rancid, fishy or cabbage odor</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>3996</id><symptom>renal enlargement</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>2461</id><symptom>renal failure, acute/chronic</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>4097</id><symptom>renal failure, chronic</symptom><category /></symtomp><symtomp><id>1995</id><symptom>rickets</symptom><category>ENDOCRINE SYSTEM | SKELATAL DEFECT</category></symtomp><symtomp><id>3199</id><symptom>thrombopenia, thrombocytopenia</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2123</id><symptom>tubulopathy / renal tubulopathy</symptom><category>GENITOURINARY TRACT</category></symtomp><symtomp><id>2329</id><symptom>unusual odor / odour</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1980</id><symptom>vomiting</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp></Symptoms><Metabolites><metabolite><id>1404</id><name>Coagulopathy/Coagulation factors</name><specimen /><value /><min>    </min><max>    </max><unit /><age /><method /><comment /></metabolite><metabolite><id>1584</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>1.50</min><max>3.90</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1651</id><name>Methionine</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>2.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1656</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>4.10</min><max>23.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1676</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>1.40</min><max>14.60</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1689</id><name>Succinylacetone</name><specimen>urine</specimen><value>normal/inc</value><min>0.60</min><max>4.70</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1700</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>2.60</min><max>22.80</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1731</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>45.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1738</id><name>Succinylacetone</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>410.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1774</id><name>Methionine</name><specimen>urine</specimen><value>normal/inc</value><min>13.00</min><max>22.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1779</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>1100.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1795</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>36.00</min><max>69.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1796</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>470.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1804</id><name>5-Aminolevulinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1821</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>8.00</min><max>110.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1879</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>16.00</min><max>23.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1880</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>14.00</min><max>34.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1882</id><name>Methionine</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>16.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1956</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>9.00</min><max>45.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1957</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>13.00</min><max>41.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>1969</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>34.00</min><max>112.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1970</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>19.00</min><max>119.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1971</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>35.00</min><max>107.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>2076</id><name>Succinylacetone</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>0.02</max><unit>&#956;mol/l</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>2091</id><name>5-Aminolevulinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>2148</id><name>Quick</name><specimen>blood</specimen><value>decreased</value><min>70.00</min><max>130.00</max><unit>%</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>2150</id><name>alpha-Fetoprotein</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>20.00</max><unit>mg/ml</unit><age>Adulthood</age><method /><comment /></metabolite><metabolite><id>2151</id><name>alpha-Fetoprotein</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>6.00</max><unit>ng/ml</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>71</id><name>4-Hydroxycyclohexylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>68</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>28.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1363</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>59.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>GCMS</method><comment /></metabolite><metabolite><id>1362</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>240.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>675</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>677</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>678</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>7.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>674</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>11.50</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>676</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.30</min><max>5.80</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>680</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>682</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>683</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>66</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>679</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>21.30</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1860</id><name>5-Aminolevulinic acid</name><specimen>urine</specimen><value>increased</value><min>1.20</min><max>4.40</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1159</id><name>alpha-Fetoprotein</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>18000.00</max><unit>ng/dl</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1160</id><name>alpha-Fetoprotein</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>28.00</max><unit>ng/ml</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>1034</id><name>Coagulopathy/Coagulation factors</name><specimen>plasma</specimen><value>increased</value><min>    </min><max>    </max><unit>no data</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1885</id><name>D-Glucose</name><specimen>urine</specimen><value>increased</value><min>12.50</min><max>58.40</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1523</id><name>5-Aminolevulinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>12.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>1174</id><name>5-Aminolevulinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>20.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1201</id><name>Ferric chloride reaction</name><specimen>urine</specimen><value /><min>    </min><max>    </max><unit>negative</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>1413</id><name>D-Glucose</name><specimen>urine</specimen><value /><min>100.00</min><max>209.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment>day 1-7</comment></metabolite><metabolite><id>1609</id><name>D-Glucose</name><specimen>urine</specimen><value /><min>12.50</min><max>58.40</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1844</id><name>D-Glucose</name><specimen>urine</specimen><value /><min>76.00</min><max>810.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>47</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>2.60</min><max>5.50</max><unit>mmol/l</unit><age>Adolescence</age><method /><comment>fasted</comment></metabolite><metabolite><id>281</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>2.60</min><max>5.50</max><unit>mmol/l</unit><age>Adulthood</age><method /><comment>fasted</comment></metabolite><metabolite><id>282</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>3.30</min><max>5.50</max><unit>mmol/l</unit><age>Childhood</age><method /><comment>fasted</comment></metabolite><metabolite><id>280</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>1.10</min><max>3.30</max><unit>mmol/l</unit><age>premature</age><method /><comment /></metabolite><metabolite><id>283</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>2.20</min><max>3.30</max><unit>mmol/l</unit><age>Neonatal</age><method /><comment>fasted, 1 day</comment></metabolite><metabolite><id>46</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>2.80</min><max>5.00</max><unit>mmol/l</unit><age>Neonatal</age><method /><comment>fasted, &gt;1 day</comment></metabolite><metabolite><id>399</id><name>D-Glucose</name><specimen>cerebrospinal fluid</specimen><value /><min>1.70</min><max>3.70</max><unit>mmol/l</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>1134</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>2.70</min><max>4.50</max><unit>mmol/l</unit><age /><method /><comment /></metabolite><metabolite><id>1135</id><name>D-Glucose</name><specimen>plasma</specimen><value /><min>3.00</min><max>4.30</max><unit>mmol/l</unit><age /><method /><comment /></metabolite><metabolite><id>490</id><name>D-Glucose</name><specimen>blood</specimen><value>decreased</value><min>2.60</min><max>5.50</max><unit>mmol/l</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>333</id><name>D-Glucose</name><specimen>blood</specimen><value>decreased</value><min>2.60</min><max>5.50</max><unit>mmol/l</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>334</id><name>D-Glucose</name><specimen>blood</specimen><value>decreased</value><min>2.60</min><max>5.50</max><unit>mmol/l</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>1881</id><name>Methionine</name><specimen>urine</specimen><value>decreased</value><min>3.00</min><max>17.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1924</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>2.00</min><max>23.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1763</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>0.00</min><max>43.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1494</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>11.00</min><max>31.00</max><unit>&#956;mol/l</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>760</id><name>Methionine</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>29.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1510</id><name>Methionine</name><specimen>urine</specimen><value>increased</value><min>7.00</min><max>27.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1511</id><name>Methionine</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>29.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>699</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>11.00</min><max>30.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1161</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>10.00</min><max>60.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1162</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>11.00</min><max>31.00</max><unit>&#956;mol/l</unit><age>Infancy</age><method>HPLC</method><comment /></metabolite><metabolite><id>1288</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>6.00</min><max>46.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1289</id><name>Methionine</name><specimen>plasma</specimen><value>increased</value><min>9.00</min><max>59.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1556</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>69</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1383</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>    </min><max>6.40</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1384</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>    </min><max>781.00</max><unit>mmol/mol creatinine</unit><age>premature</age><method /><comment /></metabolite><metabolite><id>405</id><name>Phosphate</name><specimen>serum</specimen><value>decreased</value><min>1.70</min><max>3.50</max><unit>mmol/l</unit><age>premature</age><method /><comment /></metabolite><metabolite><id>406</id><name>Phosphate</name><specimen>serum</specimen><value>decreased</value><min>1.40</min><max>3.00</max><unit>mmol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>407</id><name>Phosphate</name><specimen>serum</specimen><value>decreased</value><min>1.30</min><max>1.90</max><unit>mmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>408</id><name>Phosphate</name><specimen>serum</specimen><value>decreased</value><min>0.60</min><max>1.50</max><unit>mmol/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>1038</id><name>Phosphate</name><specimen>serum</specimen><value>decreased</value><min>1.60</min><max>2.60</max><unit>mmol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>70</id><name>Succinylacetone</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>0.10</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>1390</id><name>Succinylacetone</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>0.10</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1158</id><name>Thrombocytes, Platelets</name><specimen>blood</specimen><value>decreased</value><min>100.00</min><max>350.00</max><unit>x1000/&#181;l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1157</id><name>Thrombocytes, Platelets</name><specimen>blood</specimen><value>decreased</value><min>150.00</min><max>400.00</max><unit>x1000/&#181;l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>155</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>6.00</min><max>55.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>870</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>9.00</min><max>48.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1553</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>6.00</min><max>26.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1517</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>11.00</min><max>54.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>53</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>38.00</min><max>147.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1298</id><name>L-Tyrosine</name><specimen>blood</specimen><value>increased</value><min>29.06</min><max>178.41</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1299</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>14.00</min><max>115.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>19</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>22.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1333</id><name>Uracil</name><specimen>urine</specimen><value>increased</value><min>10.00</min><max>50.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7973</id><title>First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.</title><author>&#196;&#228;rel&#228; L,</author><journal>J Pediatr Endocrinol Metab</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>8179</id><title>Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia t</title><author>Yeo M,</author><journal>Ann Clin Biochem</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>8232</id><title>Type 1 tyrosinemia in Finland: a nationwide study</title><author>&#196;&#228;rel&#228; L,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>281</pages><co_aut /></literature><literature><id>6438</id><title>Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms</title><author>Moreira-Silva H,</author><journal>Eur J Pediatr</journal><year>2019</year><book /><volume>178</volume><number>4</number><pages>515-523</pages><co_aut>et al.</co_aut></literature><literature><id>6663</id><title>Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1</title><author>Hickey RD,</author><journal>Cell Transplant</journal><year>2019</year><book /><volume>28</volume><number>1</number><pages>79-88</pages><co_aut>et al.</co_aut></literature><literature><id>6664</id><title>The Unique Spectrum of Mutations in Patients with Hereditary Tyrosinemia Type 1 in Different Regions of the Russian Federation</title><author>Baydakova GV,</author><journal>JIMD Rep</journal><year>2019</year><book /><volume>45</volume><number>0</number><pages>89-93</pages><co_aut>et al.</co_aut></literature><literature><id>7266</id><title>[Clinical and genetic analysis of a patient with tyrosinemia type I but without elevated succinylacetone]</title><author>Guo L,</author><journal>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</journal><year>2019</year><book /><volume>36</volume><number>5</number><pages>472-476</pages><co_aut>Jiao B, Liu F</co_aut></literature><literature><id>7303</id><title>Biomarkers of Micronutrients in Regular Follow-Up for Tyrosinemia Type 1 and Phenylketonuria Patients</title><author>van Vliet K,</author><journal>Nutrients</journal><year>2019</year><book /><volume>11</volume><number>9</number><pages>E2011</pages><co_aut>et al.</co_aut></literature><literature><id>6082</id><title>Late-onset cobalamin C deficiency Chinese sibling patients with neuropsychiatric presentations</title><author>Wang SJ,</author><journal>Metab Brain Dis</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6658</id><title>Discontinuation of NTBC after liver transplantation in tyrosinemia type 1</title><author>Kurihara K,</author><journal>Pediatr Int</journal><year>2018</year><book /><volume>60</volume><number>11</number><pages>1039-1041</pages><co_aut>et al.</co_aut></literature><literature><id>6659</id><title>Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day</title><author>Kienstra NS,</author><journal>J Inherit Metab Dis</journal><year>2018</year><book /><volume>41</volume><number>2</number><pages>181-186</pages><co_aut>et al.</co_aut></literature><literature><id>6660</id><title>Three Cases of Hereditary Tyrosinaemia Type 1: Neuropsychiatric Outcomes and Brain Imaging Following Treatment with NTBC</title><author>Walker H,</author><journal>JIMD Rep</journal><year>2018</year><book /><volume>40</volume><number>0</number><pages>97-103</pages><co_aut>et al.</co_aut></literature><literature><id>4977</id><title>Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy</title><author>Stinton C,</author><journal>Orphanet J Rare Dis</journal><year>2017</year><book /><volume>12</volume><number>1</number><pages>48</pages><co_aut>et al.</co_aut></literature><literature><id>5173</id><title>Remaining Challenges in the Treatment of Tyrosinemia from the Clinicians Viewpoint</title><author>Mitchell GA,</author><journal>Adv Exp Med Biol</journal><year>2017</year><book /><volume>959</volume><number>0</number><pages>205-213</pages><co_aut>Yang H</co_aut></literature><literature><id>5573</id><title>Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review</title><author>Geppert J,</author><journal>Orphanet J Rare Dis</journal><year>2017</year><book /><volume>12</volume><number>1</number><pages>154</pages><co_aut>et al.</co_aut></literature><literature><id>5574</id><title>Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)</title><author>Das AM</author><journal>Appl Clin Genet</journal><year>2017</year><book /><volume>10</volume><number>0</number><pages>43-48</pages><co_aut /></literature><literature><id>5575</id><title>Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening</title><author>Das AM,</author><journal>Adv Exp Med Biol</journal><year>2017</year><book /><volume>959</volume><number>0</number><pages>125-132</pages><co_aut>Mayorandan S, Janzen N</co_aut></literature><literature><id>5715</id><title>Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses</title><author>Kienstra NS,</author><journal>J Inherit Metab Dis</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6046</id><title>Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient FAH alleles</title><author>Yang H,</author><journal>Mol Genet Metab Rep</journal><year>2017</year><book /><volume>14</volume><number>0</number><pages>55-58</pages><co_aut>et al.</co_aut></literature><literature><id>6083</id><title>Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review</title><author>Chen M,</author><journal>Medicine (Baltimore)</journal><year>2017</year><book /><volume>96</volume><number>43</number><pages>e8284</pages><co_aut>et al.</co_aut></literature><literature><id>6656</id><title>Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients</title><author>van Ginkel WG,</author><journal>Adv Exp Med Biol</journal><year>2017</year><book /><volume>959</volume><number>0</number><pages>111-122</pages><co_aut>et al.</co_aut></literature><literature><id>6657</id><title>Dietary Considerations in Tyrosinemia Type I</title><author>van Spronsen FJ,</author><journal>Adv Exp Med Biol</journal><year>2017</year><book /><volume>959</volume><number>0</number><pages>197-204</pages><co_aut>et al.</co_aut></literature><literature><id>6661</id><title>Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations</title><author>Chinsky JM,</author><journal>Genet Med</journal><year>2017</year><book /><volume>19</volume><number>12</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6662</id><title>Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia</title><author>Honar N,</author><journal>Iran J Child Neurol</journal><year>2017</year><book /><volume>11</volume><number>4</number><pages>66-70</pages><co_aut>et al.</co_aut></literature><literature><id>6667</id><title>Abnormal social behavior in mice with tyrosinemia type I is associated with an increase of myelin in the cerebral cortex</title><author>Moore ME,</author><journal>Metab Brain Dis</journal><year>2017</year><book /><volume>32</volume><number>6</number><pages>1829-1841</pages><co_aut>et al.</co_aut></literature><literature><id>6668</id><title>Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice</title><author>Hillgartner MA,</author><journal>J Inherit Metab Dis</journal><year>2016</year><book /><volume>39</volume><number>5</number><pages>673-682</pages><co_aut>et al.</co_aut></literature><literature><id>3232</id><title>Neonatal screening for hereditary tyrosinaemia: are we there yet?</title><author>Hadzic N,</author><journal>Arch Dis Child</journal><year>2015</year><book /><volume>100</volume><number>8</number><pages>720-721</pages><co_aut>Vara R</co_aut></literature><literature><id>3233</id><title>Inherited metabolic disorders presenting as acute liver failure in newborns and young children: Kings College Hospital experien</title><author>Hegarty R,</author><journal>Eur J Pediatr</journal><year>2015</year><book /><volume>174</volume><number>10</number><pages>1387-1392</pages><co_aut>et al.</co_aut></literature><literature><id>3240</id><title>50 years ago in The Journal of Pediatrics: Tyrosinemia--an inborn error of tyrosine metabolism with cirrhosis of the liver and </title><author>Andersson HC</author><journal>J Pediatr</journal><year>2015</year><book /><volume>166</volume><number>4</number><pages>896</pages><co_aut /></literature><literature><id>6655</id><title>Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented?</title><author>van Vliet D,</author><journal>JIMD Rep</journal><year>2015</year><book /><volume>18</volume><number>0</number><pages>117-124</pages><co_aut>et al.</co_aut></literature><literature><id>3230</id><title>Tyrosinemia type 1: an overview of nursing care</title><author>Barnby E</author><journal>Pediatr Nurs</journal><year>2014</year><book /><volume>40</volume><number>2</number><pages>61-68</pages><co_aut /></literature><literature><id>3231</id><title>Recommendations for the management of tyrosinaemia type 1</title><author>de Laet C,</author><journal>Orphanet J Rare Dis</journal><year>2013</year><book /><volume>8</volume><number>0</number><pages>8</pages><co_aut>et al.</co_aut></literature><literature><id>5576</id><title>Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommen</title><author>Mak CM,</author><journal>Clin Biochem</journal><year>2013</year><book /><volume>46</volume><number>1</number><pages>155-159</pages><co_aut>et al.</co_aut></literature><literature><id>5577</id><title>Hypermethioninemias of genetic and non-genetic origin: A review</title><author>Mudd SH</author><journal>Am J Med Genet C Semin Med Genet</journal><year>2011</year><book /><volume>157</volume><number>1</number><pages>3-32</pages><co_aut /></literature><literature><id>2803</id><title>Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment</title><author>Schlump JU,</author><journal>J Inherit Metab Dis</journal><year>2008</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>2622</id><title>Cardiomyopathy in tyrosinaemia type I is common but usually benign</title><author>Arora N</author><journal>J Inherit Metab Dis</journal><year>2006</year><book /><volume>29</volume><number>0</number><pages>54-57</pages><co_aut>et al.</co_aut></literature><literature><id>1953</id><title>Tyrosinaemia type I-de novo mutation in liver tissue suppressing an inborn splicing defect</title><author>Bliksrud YT</author><journal>J Mol Med</journal><year>2005</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>1954</id><title>Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I</title><author>Andre N</author><journal>J Inherit Metab Dis</journal><year>2005</year><book /><volume>28</volume><number>1</number><pages>103-106</pages><co_aut>et al.</co_aut></literature><literature><id>1956</id><title>Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedion</title><author>van Spronsen FJ</author><journal>J Pediatr Gastroenterol Nutr</journal><year>2005</year><book /><volume>40</volume><number>1</number><pages>90-93</pages><co_aut>et al.</co_aut></literature><literature><id>1952</id><title>Feeding infants with undiluted goats milk can mimic tyrosinaemia type 1</title><author>Hendriksz CJ</author><journal>Acta Paediatr</journal><year>2004</year><book /><volume>93</volume><number>4</number><pages>552-553</pages><co_aut>Walter JH</co_aut></literature><literature><id>7231</id><title>N-acetyl tyrosyluria caused by parenteral or enteral administration of N-acetyl-L-tyrosine: differentiation from hereditary and</title><author>Korman SH,</author><journal>J Pediatr Gastroenterol Nutr</journal><year>2004</year><book /><volume>39</volume><number>1</number><pages>95-100</pages><co_aut>Gutman A.</co_aut></literature><literature><id>1489</id><title>Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia</title><author>Demers SI</author><journal>Hum Pathol</journal><year>2003</year><book /><volume>34</volume><number>12</number><pages>1313-1320</pages><co_aut>et al.</co_aut></literature><literature><id>1951</id><title>Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC</title><author>Gissen P</author><journal>J Inherit Metab Dis</journal><year>2003</year><book /><volume>26</volume><number>1</number><pages>13-16</pages><co_aut>et al.</co_aut></literature><literature><id>5172</id><title>Tyrosinemia: a review.</title><author>Russo PA,</author><journal>Pediatr Dev Pathol</journal><year>2001</year><book /><volume>4</volume><number>3</number><pages>212-221</pages><co_aut>Mitchell GA, Tanguay RM</co_aut></literature><literature><id>1003</id><title>5-Oxoprolinuria in patients with and without defects in the gamma-glutamyl cycle</title><author>Mayatepek E</author><journal>Eur J Pediatr</journal><year>1999</year><book /><volume>158</volume><number>0</number><pages>221-225</pages><co_aut /></literature><literature><id>1062</id><title>Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure&lt;</title><author>Croffie JM</author><journal>Pediatrics</journal><year>1999</year><book /><volume>103</volume><number>3</number><pages>675-678</pages><co_aut>Gupta SK, Chong SK, Fitzgerald JF </co_aut></literature><literature><id>1065</id><title>[Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I]</title><author>Barkaoui E</author><journal>Arch Pediatr</journal><year>1999</year><book /><volume>6</volume><number>5</number><pages>540-544</pages><co_aut>Debray D, Habes D, Ogier H, Bernard O</co_aut></literature><literature><id>953</id><title>Tyrosinemia type I and NTBC (2-(2.nitro-4-trifluorormethylbenzoyl)-1-3-cyclohexadione)</title><author>Holme E</author><journal>J Inherit Metab Dis</journal><year>1998</year><book /><volume>21</volume><number>0</number><pages>507-517</pages><co_aut>Lindstedt S</co_aut></literature><literature><id>446</id><title>Screening for tyrosinaemia type I</title><author>Hutchesson AC</author><journal>Arch Dis Child Fetal Neonatal Ed.</journal><year>1996</year><book /><volume>74</volume><number>0</number><pages>F191-F194</pages><co_aut>Hall SK, Preece MA, Green A</co_aut></literature><literature><id>121</id><title>Hypertyrosinemia</title><author>Mitchell GA</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>1</volume><number>0</number><pages>1077-1106</pages><co_aut>et al.</co_aut></literature><literature><id>131</id><title>Treatment of tyrosinemia type I with an enzyme inhibitor (NTBC)</title><author>Holme E</author><journal>International Pediatrics</journal><year>1995</year><book /><volume>10</volume><number>1</number><pages>41-43</pages><co_aut>Lindstedt S, Lock EA</co_aut></literature><literature><id>498</id><title>Tyrosinaemia -- treatment and outcome</title><author>Kvittingen EA</author><journal>J Inherit Metab Dis</journal><year>1995</year><book /><volume>18</volume><number>0</number><pages>375-379</pages><co_aut /></literature><literature><id>499</id><title>Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation</title><author>van Spronsen FJ</author><journal>J Inherit Metab Dis</journal><year>1995</year><book /><volume>18</volume><number>0</number><pages>111-114</pages><co_aut>et al.</co_aut></literature><literature><id>1064</id><title>Diagnosis and management of tyrosinemia type I</title><author>Holme E</author><journal>Curr Opin Pediatr</journal><year>1995</year><book /><volume>7</volume><number>6</number><pages>726-732</pages><co_aut>Lindstedt S </co_aut></literature><literature><id>221</id><title>Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation</title><author>Noble-Jamieson G</author><journal>Arch Dis Child</journal><year>1994</year><book /><volume>70</volume><number>0</number><pages>544-545</pages><co_aut>et al.</co_aut></literature><literature><id>7230</id><title>The excretion of N-acetyltyrosine in tyrosyluria</title><author>Dubovsky J,</author><journal>Clin Chim Acta</journal><year>1965</year><book /><volume>12</volume><number>1</number><pages>118-119</pages><co_aut>Dubovska E</co_aut></literature><literature><id>3211</id><title>Physicians Guide to the Laboratory Diagnosis of Metabolic Diseases</title><author>Blau N</author><journal>Springer</journal><year>0</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature></Literatures></Disease>